These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 24191893

  • 1. Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study.
    Ye Z, Zhang L, Xu L, Shi W, Hu H, Shi X, Zhong W, Hou S, Yan H, Zhang B, Xia Y, Wang W, Feng Z, Wang L, Liang Y.
    Nephrology (Carlton); 2014 Jan; 19(1):40-6. PubMed ID: 24191893
    [Abstract] [Full Text] [Related]

  • 2. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.
    Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
    [Abstract] [Full Text] [Related]

  • 3. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
    Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
    Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
    [Abstract] [Full Text] [Related]

  • 4. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 5. Evidence for abundant presence of chymase-positive mast cells in the kidneys of patients with immunoglobulin A nephropathy: effect of combination therapy with prednisolone and angiotensin II receptor blocker valsartan.
    Konishi Y, Morikawa T, Okada N, Maeda I, Kitabayashi C, Yoshioka K, Okumura M, Nishiyama A, Ueda M, Takai S, Miyazaki M, Imanishi M.
    Hypertens Res; 2008 Aug; 31(8):1517-24. PubMed ID: 18971525
    [Abstract] [Full Text] [Related]

  • 6. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M, Takeya Y, Tatara Y, Yamamoto K, Onishi M, Maekawa Y, Kamide K, Rakugi H.
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

  • 8. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 9. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
    Medicina (B Aires); 2007 Jan; 67(5):445-50. PubMed ID: 18051227
    [Abstract] [Full Text] [Related]

  • 10. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL, Ekhlas A, Nguyen JM, Moranne O.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [Abstract] [Full Text] [Related]

  • 11. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
    Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P.
    Kidney Int; 2003 Mar; 63(3):1094-103. PubMed ID: 12631093
    [Abstract] [Full Text] [Related]

  • 12. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I.
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [Abstract] [Full Text] [Related]

  • 13. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.
    Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
    [Abstract] [Full Text] [Related]

  • 14. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
    Oguzhan N, Cilan H, Sipahioglu M, Unal A, Kocyigit I, Kavuncuoglu F, Arikan T, Akpek M, Elcik D, Sahin O, Gulme E, Pala C, Tokgoz B, Utas C, Oguzhan A, Oymak O.
    Ren Fail; 2013 Nov; 35(4):434-9. PubMed ID: 23413781
    [Abstract] [Full Text] [Related]

  • 15. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 16. A drug safety evaluation of valsartan.
    Fogari R, Zoppi A.
    Expert Opin Drug Saf; 2011 Mar 21; 10(2):295-303. PubMed ID: 21142805
    [Abstract] [Full Text] [Related]

  • 17. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB.
    J Am Soc Hypertens; 2012 Mar 21; 6(5):338-45. PubMed ID: 22995802
    [Abstract] [Full Text] [Related]

  • 18. Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
    Saikawa T, Sasaki J, Biro S, Kono S, Otonari T, Ikeda Y, DDV investigators.
    Hypertens Res; 2010 Sep 21; 33(9):886-91. PubMed ID: 20555331
    [Abstract] [Full Text] [Related]

  • 19. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.
    Jo YI, Na HY, Moon JY, Han SW, Yang DH, Lee SH, Park HC, Choi HY, Lim SD, Kie JH, Lee YK, Shin SK.
    Korean J Intern Med; 2016 Mar 21; 31(2):335-43. PubMed ID: 26874511
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 21; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.